AZNAstraZenecaRunning, no new patients
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Non Small Cell Lung Carcinoma NSCLC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 669 (final count)
- Started
- Jan 2, 2017
- Main results expected
- Oct 27, 2022
- Fully finished
- Jun 30, 2026
- Results posted
- Dec 26, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]
OS in Participants With LREM
Measured over: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03003962 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC